Literature DB >> 6992836

Epidermolysis bullosa acquisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients.

C Nieboer, D M Boorsma, M J Woerdeman, G L Kalsbeek.   

Abstract

Four patients with the clinical picture of epidermolysis bullosa acquisita were investigated. Biopsies were taken from the involved and uninvolved areas of the skin and the immunohistochemical and microscopic changes were studied. Direct immunofluorescence showed deposition of IgG and C3/4 in a linear or norched pattern along the epidermal basement membrane in both the involved and the uninvolved skin. In addition IgA (3/4), IgM (1/4), C4 (3/4) and properdin (3/4) could be detected. Indirect immunofluorescence revealed the presence of circulating antibodies against inter alia the epithelial basement membrane zone in one patient. Routine electron microscopy showed that the blister was situated in the dermis leaving the basal lamina in the roof of the blister. With immunoelectron microscopy using peroxidase-labelled antibody the in vivo deposition of IgG was observed just beneath the basal lamina in the dermis of both the perilesional and the uninvolved skin. These observations show that epidermolysis bullosa acquisita is a distinct entity, in which autoimmune mechanisms might possibly play a role.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992836     DOI: 10.1111/j.1365-2133.1980.tb06550.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

3.  Antigen specificities of antibasement membrane zone antibodies: immunofluorescence and Western immunoblotting studies.

Authors:  T Muramatsu; T Shirai; T Iida; Y Yamashina; K Sakamoto
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

4.  Specific affinity between fibronectin and the epidermolysis bullosa acquisita antigen.

Authors:  D T Woodley; E J O'Keefe; J A McDonald; M J Reese; R A Briggaman; W R Gammon
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Disseminated cicatricial pemphigoid in a child and in an adult. Ultrastructural diagnostic criteria and differential diagnosis with special reference to acquired epidermolysis bullosa.

Authors:  I Hausser; M Fartasch; E Schleiermacher; I Anton-Lamprecht
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen.

Authors:  Cassian Sitaru; Sidonia Mihai; Christoph Otto; Mircea T Chiriac; Ingrid Hausser; Barbara Dotterweich; Hitoshi Saito; Christian Rose; Akira Ishiko; Detlef Zillikens
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 7.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Authors:  J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen.

Authors:  D T Woodley; R E Burgeson; G Lunstrum; L Bruckner-Tuderman; M J Reese; R A Briggaman
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

10.  Epidermolysis bullosa acquisita--successful treatment with colchicine.

Authors:  M Megahed; K Scharffetter-Kochanek
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.